IP Verse

Uses Of Pthrp Analogue In Reducing Fracture Risk - EP3265115

The patent EP3265115 was granted to Radius Health on Jun 22, 2022. The application was originally filed on Mar 3, 2016 under application number EP16759540A. The patent is currently recorded with a legal status of "Revoked".

EP3265115

RADIUS HEALTH
Application Number
EP16759540A
Filing Date
Mar 3, 2016
Status
Revoked
Nov 17, 2023
Publication Date
Jun 22, 2022
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

AERAMar 21, 2023AERAADMISSIBLE

Patent Citations (6) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
EXAMINATIONWO2009137093
EXAMINATIONWO2010022176
INTERNATIONAL-SEARCH-REPORTUS2010016223
INTERNATIONAL-SEARCH-REPORTWO2014004465
SEARCHWO2012145665
SEARCHWO2017062922

Non-Patent Literature (NPL) Citations (29) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
EXAMINATION- Anonymous, "FOSAMAX - HIGHLIGHTS OF PRESCRIBING INFORMATION", (20120201), pages 1 - 24, URL: http://web.archive.org/web/20130824100835if_/http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021575s017lbl.pdf, (20210506), XP055802143
EXAMINATION- Anonymous, "NCT01343004: Study to Evaluate the Safety and Efficacy of BA058 (Abaloparatide) for Prevention of Fracture in Postmenopausal Women (ACTIVE)", (20150126), pages 1 - 6, URL: https://clinicaltrials.gov/ct2/history/NCT01343004?V_13=View#StudyPageTop, (20200617), XP055706128
EXAMINATION- COSMAN F, "Eighteen months of treatment with abaloparatide followed by six months of treatment with alendronate in postmenopausal women with osteoporosis - Results of the ACTIVExtend trial", EMBASE, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, (20150201), Database accession no. EMB-620768919
EXAMINATION- DOHMEIER D ET AL, "Transdermal delivery of abaloparatide: Optimization of the pharmacokinetic profile in cynomologus monkeys", EMBASE, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, (20150201), Database accession no. EMB-620769961
EXAMINATION- FITZPATRICK L ET AL, "Effects of abaloparatide on major osteoporotic fracture incidence in postmenopausal women with osteoporosis - Results of the Phase 3 ACTIVE trial", EMBASE, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, (20150201), Database accession no. EMB-620769127
EXAMINATION- HARRIS A ET AL, "Response rates for hip, femoral neck and lumbar spine BMD are higher for patients treated with abaloparatide when compared to placebo or teriparatide - Results of the ACTIVE trial", EMBASE, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, (20150201), Database accession no. EMB-620769884
EXAMINATION- JOURNAL OF BONE AND MINERAL RESEARCH 20150201 JOHN WILEY AND SONS INC. NLD, (20150201), vol. 30, no. Supplement 1, ISSN 1523-4681
OPPOSITION- (20140000), page 28
OPPOSITION- AMUGONGO et al., Bone, (20140000), vol. 67, pages 257 - 268
OPPOSITION- CENTER, Curr Osteoporos Rep, (20100000), vol. 8, pages 227 - 234
OPPOSITION- PAPAPOULOS, Ann. N.Y. Acad. Sci., (20110000), vol. 1218, pages 15 - 32
OPPOSITION- Radius Announces Positive Phase 3 Top-Line Results for Its Investigational Drug Abaloparatide-SC in Postmenopausal Women With Severe Osteoporosis, (20141221), URL: https://web.archive.org/web/ 20150928 070545
SEARCH- Anonymous, "Radius Announces Positive Phase 3 Top-Line Results for Its Investigational Drug Abaloparatide-SC in Postmenopausal Women With Severe Osteoporosis | Radius Health, Inc.", (20141222), pages 1 - 8, URL: http://ir.radiuspharm.com/news-releases/news-release-details/radius-announces-positive-phase-3-top-line-results-its?ReleaseID=888584, (20180911), XP055506045 [X] 1,3-6,8,13,15 * page 2 *
SEARCH- Anonymous, "Radius Announces Positive Phase 3 Top-Line Results - MPM Capital", (20141222), pages 1 - 7, URL: http://www.mpmcapital.com/press/radius-announces-positive-phase-3-top-line-results/, (20180911), XP055506014 [X] 1,3-6,8,13 * page 2 *
SEARCH- BRIGITTE UEBELHART ET AL, "Maladies osseusses", REV MED SUISSE, (20160113), vol. 12, no. 500, pages 49 - 54, XP055505897 [XP] 1,3-6,8,13,15 * page 50 *
SEARCH- COSMAN F, "Eighteen months of treatment with abaloparatide followed by six months of treatment with alendronate in postmenopausal women with osteoporosis - Results of the ACTIVExtend trial", EMBASE, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, (20151009), Database accession no. EMB-620768919, XP002784616 [XP] 1,3-6,8,13,15 * abstract *
SEARCH- DOHMEIER D ET AL, "Transdermal delivery of abaloparatide: Optimization of the pharmacokinetic profile in cynomologus monkeys", EMBASE, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, (20151009), Database accession no. EMB-620769961, XP002784613 [XP] 1,3-6,8,13,15 * abstract *
SEARCH- FITZPATRICK L ET AL, "Effects of abaloparatide on major osteoporotic fracture incidence in postmenopausal women with osteoporosis - Results of the Phase 3 ACTIVE trial", EMBASE, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, (20151009), Database accession no. EMB-620769127, XP002784615 [XP] 1,3-6,8,13,15 * abstract *
SEARCH- HARRIS A ET AL, "Response rates for hip, femoral neck and lumbar spine BMD are higher for patients treated with abaloparatide when compared to placebo or teriparatide - Results of the ACTIVE trial", EMBASE, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, (20151009), Database accession no. EMB-620769884, XP002784614 [XP] 1,3-6,8,13,15 * abstract *
SEARCH- JOURNAL OF BONE AND MINERAL RESEARCH 20150201 JOHN WILEY AND SONS INC. NLD, (20151217), vol. 30, no. Supplement 1, ISSN 1523-4681
SEARCH- PAUL D. MILLER ET AL, "Effects of Abaloparatide on Vertebral and Non-Vertebral Fracture Incidence in Postmenopausal Women with Osteoporosis - Results of the Phase 3 Active Trial : New Discoveries in Bone Health and Disease", ENDOCRINE SOCIETY'S 97TH ANNUAL MEETING AND EXPO, (20150305), pages 1 - 2, XP055506001 [XP] 1,3-6,8,13,15 * page 1 *
SEARCH- PAUL MILLER ET AL, "Treatment with Abaloparatide Significantly Reduces Wrist Fractures Compared to Teriparatide - Results of the Phase 3 ACTIVE Trial", ECTS-IBMS 2015, (20150428), pages 1 - 4, XP055579321 [IP] 1-3,5-15 * page 2 * [Y] 1-15
SEARCH- JANINA M PATSCH ET AL, "Increased cortical porosity in type 2 diabetic postmenopausal women with fragility fractures", JOURNAL OF BONE AND MINERAL RESEARCH, US, (20130115), vol. 28, no. 2, doi:10.1002/jbmr.1763, ISSN 0884-0431, pages 313 - 324, XP055309972 [Y] 1-3,5-15 * page 314 *
SEARCH- OEI LING ET AL, "Diabetes, Diabetic Complications, and Fracture Risk", CURRENT OSTEOPOROSIS REPORTS, CURRENT SCIENCE INC, US, vol. 13, no. 2, doi:10.1007/S11914-015-0260-5, ISSN 1544-1873, (20150204), pages 106 - 115, (20150204), XP035465158 [Y] 1-3,5-15 * page 110 *
SEARCH- SERGE FERRARI, "Future directions for new medical entities in osteoporosis", BAILLIERE'S BEST PRACTICE AND RESEARCH. CLINICAL ENDOCRINOLOGYAND METABOLISM, GB, (20140820), vol. 28, no. 6, doi:10.1016/j.beem.2014.08.002, ISSN 1521-690X, pages 859 - 870, XP055579227 [Y] 4 * page 860 *
SEARCH- MAKRAS POLYZOIS ET AL, "Novel therapies for osteoporosis", METABOLISM, CLINICAL AND EXPERIMENTAL, (20150721), vol. 64, no. 10, doi:10.1016/J.METABOL.2015.07.011, ISSN 0026-0495, pages 1199 - 1214, XP029269396 [XP] 1,3-6,8,13,15 * page 1212 *
SEARCH- FELICIA COSMAN, "Abaloparatide: a new anabolic therapy on the horizon", BONEKEY REPORTS, (20150429), vol. 4, doi:10.1038/bonekey.2015.28, XP055506062 [XP] 1,3-6,8,13,15 * page 1 *
SEARCH- BENJAMIN Z. LEDER ET AL, "Effects of Abaloparatide, a Human Parathyroid Hormone-Related Peptide Analog, on Bone Mineral Density in Postmenopausal Women with Osteoporosis", JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, US, (20150201), vol. 100, no. 2, doi:10.1210/jc.2014-3718, ISSN 0021-972X, pages 697 - 706, XP055505823 [I] 1,3-6,8,13,15 * page 697 *
SEARCH- L. OEI ET AL, "High Bone Mineral Density and Fracture Risk in Type 2 Diabetes as Skeletal Complications of Inadequate Glucose Control: The Rotterdam Study", DIABETES CARE, US, (20130111), vol. 36, no. 6, doi:10.2337/dc12-1188, ISSN 0149-5992, pages 1619 - 1628, XP055579816 [YD] 1-3,5-15 * page 1620 *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents